Pear Therapeutics Launches Pear Prescription Digital Therapeutics Digest, Provides Roadmap for Payor Coverage Considerations
BOSTON–(COMMERCIAL THREAD) – Pear Therapeutics, Inc., in collaboration with Avalere Health, an Inovalon company, today launched the Pear Prescription Digital Therapeutics Digest (Pear PDT Digest) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021 conference. The Digest was presented during the Partner Session “Pioneering Prescription Digital Therapeutics to Transform the US Health Care System ”, and describes the results of a survey of 40 leading US payers and employers, covers their outlook of the digital prescription therapy (PDT) market landscape and addresses the questions keys around the PDT cover. The Digest is the first in a series of publications that will provide information on PDTs and the level of familiarity and management of PDTs by payers.
PDTs are a new class of therapy that uses software to treat serious illnesses. Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials to demonstrate safety and efficacy, evaluated for clearance by regulatory bodies such as the FDA, and used under the supervision of a prescribing clinician. Unlike traditional medicines, PDTs are designed to collect real-world data for use by prescribing clinicians and for the management of population health by payers and health systems.
The launch of the Digest comes at a critically important time as Americans continue to fight the growing burden of chronic disease during a global pandemic that has reduced access to care in part due to a shortage of providers.1-3 The Centers for Disease Control and Prevention (CDC) reports that 90% of the $ 3.8 trillion in annual health care spending in the United States is for people living with chronic and mental health conditions.4
“While technology continues to transform the way patients receive care, chronic disease continues to drive healthcare spending and weighs millions of patients, providers and payers. At Pear, we believe digital prescription therapies are the next therapeutic modality – the next frontier in medicine, ”said Corey McCann, MD, Ph.D., President and CEO of Pear Therapeutics. “PDTs offer patients additional avenues to overcome barriers to accessing treatment, can improve health outcomes, and potentially lower the cost of care – it’s a win for everyone. We are excited to bring healthcare payers and decision makers with the latest information and product updates with the launch of the Pear PDT Digest. ”
“PDTs will play an essential role in the treatment of the serious illnesses for which they are indicated, ”said John Neal, general manager of Market Access at Avalere Health. “Stakeholder awareness, knowledge and coverage of PDTs will be important drivers of access as more and more FDA-cleared products enter the market. ”
The basis of the Pear PDT Digest stems from engagement with industry leaders through the distribution of a survey designed to measure employer and payor knowledge about PDTs and the current considerations and perceptions that make up the coverage landscape. This Digest incorporates the results of a survey of 40 top US payers and employers on their perspective on the PDT market landscape. This project supports the efforts of key industry leaders such as GCAP to define the coverage landscape and provide advice to payers.
The Pear PDT Digest can be downloaded here.
About Avalere Health
Avalere Health is a vibrant community of innovative thinkers dedicated to solving healthcare system challenges. We know that the only way to change health care is to look at it from all angles. We dig deep into the complex layers and work closely with clients to develop a practical solution. As an Inovalon company, we value ideas and strategies based on solid data to achieve meaningful results. For more information, visit avalere.com or follow us on Twitter @avalerehealth.
About Pear Therapeutics
Pear Therapeutics is the leader in digital prescription therapies, or PDTs. Pear aims to redefine medicine by discovering, developing and delivering clinically validated software therapies to deliver better patient outcomes, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of product and product candidates across all therapeutic areas, including the top three PDTs with FDA disease treatment claims. Pear’s flagship product, reSET®, for the treatment of substance use disorders, was the first PDT to receive market authorization from the FDA to treat the disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorders, was the first PDT to receive the breakthrough designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted via the traditional 510 (k) route of the FDA while simultaneously being reviewed as part of the software pre-certification pilot program of the FDA. For more information, visit Pear at www.peartherapeutics.com.